



## **Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference**

May 19, 2026

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- [Lexeo Therapeutics, Inc.](#) (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.

The event will be webcast live under the [News & Events](#) tab in the Investors section of the Company's website. A replay of the webcast will be available on the Lexeo website following the presentation.

### **About Lexeo Therapeutics**

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

### **Media Response:**

[Media@lexeotx.com](mailto:Media@lexeotx.com)

### **Investor Response:**

Ashley Kaplowitz  
[akaplowitz@lexeotx.com](mailto:akaplowitz@lexeotx.com)